PMID- 37968944
OWN - NLM
STAT- Publisher
LR  - 20240306
IS  - 2159-9777 (Electronic)
IS  - 0279-1072 (Linking)
DP  - 2023 Nov 15
TI  - Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with 
      Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic 
      Review and Meta-Analysis.
PG  - 1-16
LID - 10.1080/02791072.2023.2278586 [doi]
AB  - There has been a resurgence in psychedelic research for managing psychiatric 
      conditions in recent years. This study aimed to present a comprehensive review of 
      the current state of the field by applying a systematic search strategy for 
      articles on the effectiveness and tolerability of four psychedelic-assisted 
      therapies (psilocybin, lysergic acid diethylamide [LSD], 
      3,4-Methylenedioxymethamphetamine [MDMA], and ayahuasca) for adults with symptoms 
      of depression, anxiety, and posttraumatic stress disorder (PTSD). Psychometric 
      scores and adverse events were pooled using random-effects meta-analysis models 
      with Hedges' g bias-corrected standardized mean differences (g) and rate ratios 
      (RR) with 95% confidence intervals (CI). Bias evaluation followed PRISMA and 
      Cochrane guidelines. Eighteen studies were identified, which suggested that 
      psychedelic therapies were well tolerated and presented a large effect size for 
      the management of depression symptoms in a transdiagnostic population with 
      psilocybin (g = -1.92, 95% CI, -2.73 to -1.11) and MDMA (g = -0.71; 95% CI, -1.39 
      to -0.03). These are promising results that complement the current literature. 
      However, evidence certainty was low to very low due to methodological 
      limitations, small sample size, blinding, study heterogeneity, and publication 
      bias. These results also highlight the need for more adequately powered studies 
      exploring these novel therapies.
FAU - Bahji, Anees
AU  - Bahji A
AUID- ORCID: 0000-0002-3490-314X
AD  - Department of Psychiatry, University of Calgary, Calgary, Canada.
AD  - Department of Community Health Sciences, University of Calgary, Calgary, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.
FAU - Lunsky, Isis
AU  - Lunsky I
AUID- ORCID: 0009-0000-6949-8036
AD  - School of Medicine, Queen's University, Kingston, Ontario, Canada.
FAU - Gutierrez, Gilmar
AU  - Gutierrez G
AUID- ORCID: 0000-0003-0337-3737
AD  - Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
FAU - Vazquez, Gustavo
AU  - Vazquez G
AUID- ORCID: 0000-0002-2918-3336
AD  - School of Medicine, Queen's University, Kingston, Ontario, Canada.
AD  - Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
LA  - eng
GR  - R25 DA037756/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20231115
PL  - United States
TA  - J Psychoactive Drugs
JT  - Journal of psychoactive drugs
JID - 8113536
SB  - IM
OTO - NOTNLM
OT  - PTSD
OT  - Psychedelic-assisted therapies
OT  - anxiety disorders
OT  - mood disorders
EDAT- 2023/11/16 06:45
MHDA- 2023/11/16 06:45
CRDT- 2023/11/16 03:40
PHST- 2023/11/16 06:45 [medline]
PHST- 2023/11/16 06:45 [pubmed]
PHST- 2023/11/16 03:40 [entrez]
AID - 10.1080/02791072.2023.2278586 [doi]
PST - aheadofprint
SO  - J Psychoactive Drugs. 2023 Nov 15:1-16. doi: 10.1080/02791072.2023.2278586.